File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Quantitative Plasma Hypermethylated DNA Markers of Undifferentiated Nasopharyngeal Carcinoma

TitleQuantitative Plasma Hypermethylated DNA Markers of Undifferentiated Nasopharyngeal Carcinoma
Authors
Issue Date2004
PublisherAmerican Association for Cancer Research.
Citation
Clinical Cancer Research, 2004, v. 10 n. 7, p. 2401-2406 How to Cite?
AbstractPurpose: Gene-specific methylation is common in primary undifferentiated nasopharyngeal carcinoma (NPC). DNA released from apoptotic or necrotic cell death including those aberrantly methylated promoter DNA of cancer cells is absorbed into the circulation as cell-free plasma DNA of the patient. This study aims at evaluation of the potential use of methylated gene promoter DNA as a serological tumor marker of primary and potentially salvageable local or nodal recurrent NPC. Experimental Design: The quantity of plasma hypermethylated gene promoters of CDH1, DAPK1, p15, p16, RASSF1A, and MLH1 of 41 NPC patients before treatment and 43 normal individuals were studied using real-time quantitative PCR. The post-treatment plasma hypermethylated CDH1, DAPK1, and p16 were also measured in 13 NPC patients with locoregional recurrence and 17 patients in remission. Results: Concentrations of cell-free circulating DNA were significantly higher in NPC patients than normal controls (28.79 ng/ml versus 16.57 ng/ml, respectively). There was no significant difference in plasma DNA concentration of EBV-positive and -negative normal individuals. Methylated DNA was detectable in plasma of NPC patients before treatment including 46% for CDH1, 42% for p16, 20% for DAPK1, 20% for p15, and 5% for RASSF1A. Hypermethylated MLH1 was not detected in plasma of all of the NPC patients and normal individuals. Aberrantly hypermethylated promoter DNA of at least one of the five genes was detectable in 29 of 41 (71%) plasma of NPC patients before treatment. Hypermethylated promoter DNA of at least one of the three genes (CDH1, DAPK1, and p16) was detectable in post-treatment plasma of 5 of 13 (38%) recurrent NPC patients and none of the patients in remission. Conclusions: Our results suggested that cell-free circulating methylated gene promoter DNA is a possibly useful serological marker in assisting in screening of primary and potentially salvageable local or regional recurrent NPC.
Persistent Identifierhttp://hdl.handle.net/10722/71898
ISSN
2015 Impact Factor: 8.738
2015 SCImago Journal Rankings: 5.314
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWong, TSen_HK
dc.contributor.authorKwong, DLWen_HK
dc.contributor.authorSham, JSTen_HK
dc.contributor.authorWei, WIen_HK
dc.contributor.authorKwong, YLen_HK
dc.contributor.authorYuen, APWen_HK
dc.date.accessioned2010-09-06T06:36:16Z-
dc.date.available2010-09-06T06:36:16Z-
dc.date.issued2004en_HK
dc.identifier.citationClinical Cancer Research, 2004, v. 10 n. 7, p. 2401-2406en_HK
dc.identifier.issn1078-0432en_HK
dc.identifier.urihttp://hdl.handle.net/10722/71898-
dc.description.abstractPurpose: Gene-specific methylation is common in primary undifferentiated nasopharyngeal carcinoma (NPC). DNA released from apoptotic or necrotic cell death including those aberrantly methylated promoter DNA of cancer cells is absorbed into the circulation as cell-free plasma DNA of the patient. This study aims at evaluation of the potential use of methylated gene promoter DNA as a serological tumor marker of primary and potentially salvageable local or nodal recurrent NPC. Experimental Design: The quantity of plasma hypermethylated gene promoters of CDH1, DAPK1, p15, p16, RASSF1A, and MLH1 of 41 NPC patients before treatment and 43 normal individuals were studied using real-time quantitative PCR. The post-treatment plasma hypermethylated CDH1, DAPK1, and p16 were also measured in 13 NPC patients with locoregional recurrence and 17 patients in remission. Results: Concentrations of cell-free circulating DNA were significantly higher in NPC patients than normal controls (28.79 ng/ml versus 16.57 ng/ml, respectively). There was no significant difference in plasma DNA concentration of EBV-positive and -negative normal individuals. Methylated DNA was detectable in plasma of NPC patients before treatment including 46% for CDH1, 42% for p16, 20% for DAPK1, 20% for p15, and 5% for RASSF1A. Hypermethylated MLH1 was not detected in plasma of all of the NPC patients and normal individuals. Aberrantly hypermethylated promoter DNA of at least one of the five genes was detectable in 29 of 41 (71%) plasma of NPC patients before treatment. Hypermethylated promoter DNA of at least one of the three genes (CDH1, DAPK1, and p16) was detectable in post-treatment plasma of 5 of 13 (38%) recurrent NPC patients and none of the patients in remission. Conclusions: Our results suggested that cell-free circulating methylated gene promoter DNA is a possibly useful serological marker in assisting in screening of primary and potentially salvageable local or regional recurrent NPC.en_HK
dc.languageengen_HK
dc.publisherAmerican Association for Cancer Research.en_HK
dc.relation.ispartofClinical Cancer Researchen_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshCarcinoma - blood - diagnosis - geneticsen_HK
dc.subject.meshCell Differentiationen_HK
dc.subject.meshCell-Free Systemen_HK
dc.subject.meshDNA - blood - geneticsen_HK
dc.subject.meshDNA Methylationen_HK
dc.subject.meshDisease-Free Survivalen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshGenetic Markersen_HK
dc.subject.meshHerpesvirus 4, Human - geneticsen_HK
dc.subject.meshHumansen_HK
dc.subject.meshImmunoglobulin A - chemistryen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshNasopharyngeal Neoplasms - blood - diagnosis - geneticsen_HK
dc.subject.meshPromoter Regions, Geneticen_HK
dc.subject.meshRecurrenceen_HK
dc.subject.meshReverse Transcriptase Polymerase Chain Reactionen_HK
dc.subject.meshSulfites - pharmacologyen_HK
dc.subject.meshTime Factorsen_HK
dc.subject.meshTumor Markers, Biologicalen_HK
dc.titleQuantitative Plasma Hypermethylated DNA Markers of Undifferentiated Nasopharyngeal Carcinomaen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1078-0432&volume=10&issue=7&spage=2401&epage=2406&date=2004&atitle=Quantitative+plasma+hypermethylated+DNA+markers+of+undifferentiated+nasopharyngeal+carcinomaen_HK
dc.identifier.emailWong, TS: thiansze@graduate.hku.hken_HK
dc.identifier.emailKwong, DLW: dlwkwong@hku.hken_HK
dc.identifier.emailWei, WI: hrmswwi@hku.hken_HK
dc.identifier.emailKwong, YL: ylkwong@hku.hken_HK
dc.identifier.authorityWong, TS=rp00478en_HK
dc.identifier.authorityKwong, DLW=rp00414en_HK
dc.identifier.authorityWei, WI=rp00323en_HK
dc.identifier.authorityKwong, YL=rp00358en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1158/1078-0432.CCR-03-0139en_HK
dc.identifier.pmid15073117-
dc.identifier.scopuseid_2-s2.0-1842583637en_HK
dc.identifier.hkuros85951en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-1842583637&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume10en_HK
dc.identifier.issue7en_HK
dc.identifier.spage2401en_HK
dc.identifier.epage2406en_HK
dc.identifier.isiWOS:000220701700026-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridWong, TS=7403531328en_HK
dc.identifier.scopusauthoridKwong, DLW=15744231600en_HK
dc.identifier.scopusauthoridSham, JST=24472255400en_HK
dc.identifier.scopusauthoridWei, WI=7403321552en_HK
dc.identifier.scopusauthoridKwong, YL=7102818954en_HK
dc.identifier.scopusauthoridYuen, APW=7006290111en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats